Findings

What do systematic reviews say?

428 questions · 430 findings · 82 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 89 · 20.7%GRADE not reported 33 · 7.7%Very low 93 · 21.6%Low 110 · 25.6%Moderate 79 · 18.4%High 26 · 6%

Scheduled surveillance vs clinical monitoring alone

Risk of access loss · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.

Scheduled surveillance showed no clear difference in risk of access loss compared with clinical monitoring alone (moderate certainty).

1 finding from 1 review

Pre‐emptive correction for haemodialysis arteriovenous access stenosis 2016 · Cochrane Headline outcomes only
RR 0.9 [0.71, 1.15]
6 studies · 662 participants
Moderate

Scheduled surveillance vs clinical monitoring alone

All‐cause mortality · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.

Scheduled surveillance showed no clear difference in mortality compared with clinical monitoring alone (low certainty).

1 finding from 1 review

Pre‐emptive correction for haemodialysis arteriovenous access stenosis 2016 · Cochrane Headline outcomes only
RR 1.38 [0.9, 2.11]
5 studies · 586 participants
Low

TACE followed by 3‐DCRT vs chemoembolisation

All‐cause mortality: at 3 years · primary hepatocellular carcinoma

TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
RR 0.8 [0.73, 0.88]
7 studies · 552 participants
Low

TACE followed by 3‐DCRT vs chemoembolisation

Serious adverse events · primary hepatocellular carcinoma

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Health‐related quality of life · primary hepatocellular carcinoma

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
RR 1.12 [0.92, 1.34]
5 studies · 438 participants
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
RR 1.67 [0.66, 4.27]
4 studies · 280 participants
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
RR 2.69 [1.34, 5.4]
2 studies · 172 participants
Very low